Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        VILLE DES SCIENCES HOECHST

        Signature(s)

        Amount
        € 27,736,686.39
        Countries
        Sector(s)
        Germany : € 27,736,686.39
        Industry : € 8,321,005.92
        Services : € 19,415,680.47
        Signature date(s)
        14/02/2003 : € 8,321,005.92
        14/02/2003 : € 19,415,680.47

        Summary sheet

        Release date
        24 August 2001
        Status
        Reference
        Signed | 14/02/2003
        20010339
        Project name
        Promoter - financial intermediary
        Ville des Sciences Höchst
        A company providing infrastructure in an industrial park
        Proposed EIB finance (Approximate amount)
        Total cost (Approximate amount)
        EUR 28 million
        Approx. EUR 94 million
        Location
        Sector(s)
        Description
        Objectives

        Construction of a multi-purpose laboratory and an adjacent office building, including laboratory support functions, to be used by companies in the fields of pharmaceutical research and biotechnology.

        The project will help to increase the competitiveness and added value of a European industry and its industrial clients. The final user of the facilities is a global player in pharmaceutical research and drug development. Given the final user’s competences in R&D and role in diffusion of innovative processes and technologies, financing the underlying R&D-efforts corresponds to the Bank’s objectives set forth in the Innovation 2000 Initiative.

        Environmental aspects
        Procurement

        The project does not require an EIA under EC Directive 97/11.All the laboratory facilities will be equipped with advanced technology analysis and experimentation systems and will operate in strict compliance with national standards for health, safety and environment.

        The procurement procedures for civil works and equipment consisted of national and international enquiries amongst a group of pre-qualified suppliers.

        Comments

        Pharmaceuticals and biotechnology

        Disclaimer

        Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
        They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

        Related publications